Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial. In the TRIUMPH-4 trial, ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, liraglutide, and tirzepatide are widely prescribed ...

We report the efficacy of a new peptide with agonism at the glucagon and GLP-1 receptors that has potent, sustained satiation-inducing and lipolytic effects. Selective chemical modification to ...

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

Fresenius Kabi announced the launch of Glucagon Emergency Kit for the treatment of severe hypoglycemic episodes in adult and pediatric patients with diabetes. Fresenius Kabi announced the launch of ...

The US Food and Drug Administration has approved the first-ever generic glucagon injection kit for the treatment of severe hypoglycemia in patients with diabetes and as a diagnostic aid. The FDA ...

In this cohort of patients with type 2 diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) use was associated with significantly lower risks of vertebral compression fractures and related ...

A glucagon injection kit is used to treat episodes of severe hypoglycemia , where a patient is either unable to treat themselves or treatment by mouth has not been successful. Glucagon is a hormone ...

Glucagon increases the production of glucose by increasing glycogenolysis and gluconeogenesis in the liver, and by reducing glycogenesis and glycolysis. The release of glucagon in response to food ...

Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034" has been added to ResearchAndMarkets.com's offering. The Europe ...